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ABSTRACT
Since 2014, guidelines for the management of lipid disorders to
reduce cardiovascular (CV) events have been updated in the United
States, the United Kingdom, Europe, and Canada. Some of these
guidelines are almost entirely evidence-based whereas others are a
mix of evidence and expert opinion. Guidelines differ on such simple
questions as to whether blood samples should be fasting or non-
fasting, and whether low-density lipoprotein cholesterol (LDL-C) or
another lipid parameter should be the primary focus of treatment.
Different risk assessment tools are recommended by different guide-
lines. Lifetime risk is highlighted in some guidelines, with the sug-
gestion that earlier treatment will reduce lifetime risk in younger
people even when short-term risk is low. Some guidelines have nu-
merical treatment targets that differ according to level of risk, while
others eschew targets but recommend statins at high or moderate
intensity to reduce LDL-C by ! 50% or 30%-50%, respectively. Statins
are the backbone of therapy in all guidelines. Ezetimibe produced a
6.4% relative risk reduction in the only large clinical outcomes trial in
which it was tested, and is recommended for high-risk patients with an
R!ESUM!E
Depuis 2014, les États-Unis, le Royaume-Uni, l’Europe et le Canada ont
proc!ed!e à l’actualisation des lignes directrices sur la prise en charge
des anomalies lipidiques pour r!eduire les !ev!enements cardiovascu-
laires (CV). Certaines de ces lignes directrices sont presque entièrement
fond!ees sur les donn!ees probantes, tandis que les autres constituent
une combinaison de donn!ees probantes et d’opinions d’experts. Les
lignes directrices diffèrent sur de simples questions quant à savoir si les
!echantillons de sang devraient être pr!elev!es à jeun ou non à jeun, et si
l’objectif principal du traitement devrait porter sur le cholest!erol à
lipoprot!eines de faible densit!e (cholest!erol LDL) ou sur un autre para-
mètre du bilan lipidique. Les diverses lignes directrices recommandent
diff!erents outils d’!evaluation des risques. Certaines lignes directrices
mettent en relief les risques à vie, et suggèrent qu’un traitement plus
pr!ecoce les r!eduira chez les personnes plus jeunes même lorsque les
risques à court terme sont faibles. Certaines lignes directrices ont des
cibles num!eriques de traitement qui diffèrent selon le niveau de
risque, tandis que d’autres !evitent les cibles, mais recommandent un
traitement par statines d’intensit!e !elev!ee ou mod!er!ee pour r!eduire
“It is the beginning of wisdom when you recognize that the best you
can do is choose which rules you want to live by, and it’s persistent and
aggravated imbecility to pretend you can live without any.”
dWallace Stegner, in All the Little Live Things
Guidelines: Quantity and Quality
A dictionary deﬁnition of guideline is a rule or instruction
that shows or tells how something should be done. Synonyms
include recommendation, instruction, direction, regulation,
rule, principle, standard, and criterion. Medical guidelines
have proliferated over the past 2 decades; as an example, the
National Guideline Clearinghouse of the Agency for Health-
care Research lists 417 different guidelines just for
hypertension.1
Medical guidelines have increasingly become evidence-
based, and less dependent on expert opinion. Level of
evidence is graded as A when on the basis of multiple ran-
domized clinical trials or meta-analyses, B when on the basis
of a single randomized trial or nonrandomized studies, and C
when on the basis of a consensus of opinion of experts, small
studies, retrospective studies, and/or registries.
In a survey of American College of Cardiology (ACC)/
American Heart Association (AHA) guidelines from 1984 to
2008, it was noted that levels of evidence only began to be
introduced in 1998.2 From 1998 to 2008, of 16 guidelines that
reported levels of evidence, comprising a total of 2711 recom-
mendations, only 314 recommendations (11%) were supported
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by level of evidence A. For acute coronary syndrome, heart
failure, and secondary prevention, more than 20% of recom-
mendations were supported by level of evidence A, compared
with < 1% of recommendations for valvular heart disease.
In the United States, the Medicare Improvements for Pa-
tients and Providers Act of 2008 directed the Institute of
Medicine to develop standards for clinical practice guidelines.3
The report, released in 2011, listed the following standards:
“Clinical practice guidelines are statements that include
recommendations intended to optimize patient care that are
informed by a systematic review of evidence and an assessment
of the beneﬁts and harms of alternative care options.
To be trustworthy, guidelines should
# be based on a systematic review of the existing
evidence;
# be developed by a knowledgeable, multidisciplinary
panel of experts and representatives from key affected
groups;
# consider important patient subgroups and patient
preferences, as appropriate;
# be based on an explicit and transparent process that
minimizes distortions, biases, and conﬂicts of interest;
# provide a clear explanation of the logical relationships
between alternative care options and health outcomes,
and provide ratings of both the quality of evidence
and the strength of the recommendations; and
# be reconsidered and revised as appropriate when
important new evidence warrants modiﬁcations of
recommendations.”
The report emphasized the importance of transparency in the
guideline development process, the need for standards or rules for
conﬂict of interest, and the appropriate level of patient and public
input into the guideline development process. The National
Guideline Clearinghouse adopted stricter rules as a result of the
Institute of Medicine report, and the number of clinical practice
guidelines that were accepted in 2014-2015 decreased to 126
from an annual average of 616 over the previous 5 years.4
With the foregoing general comments as background, let
us turn to examine several issues speciﬁc to cholesterol-
lowering guidelines.
Same Evidence, Different Conclusion
Because evidence-based guidelines are on the basis of the
same body of evidence, why do they differ? In fact, should not
all guidelines be almost identical because they are derived
from the same evidence base? The following 2 examples show
how different guideline committees can interpret the same
evidence and arrive at opposite recommendations.
It is generally agreed that fasting and nonfasting blood
samples yield similar measurements for high-density lipopro-
tein (HDL) cholesterol, and that nonfasting samples are
slightly higher for total and LDL-C, and up to 25 mg/dL
higher for triglycerides.5 The 2011 European Society of
Cardiology (ESC)/European Atherosclerosis Society (EAS)
guidelines recommended that blood sampling should be per-
formed after a 12-hour fast.6 The British National Clinical
Guideline Center (National Institute for Health and Care and
Excellence [NICE]) guidelines state that a fasting sample is
not needed,7 and the ACC/AHA guidelines state that a fasting
sample is preferred but not mandatory,8 whereas the new
Canadian guidelines recommended a nonfasting lipid deter-
mination “as a suitable alternative” to fasting levels.9 The
2016 ESC/EAS guidelines agree that a nonfasting sample is
acceptable for risk assessment, but recommend a fasting
sample for follow-up of patients with severe hyperlipidemia or
hypertriglyceridemia.10
LDL-C has traditionally been the primary measurement
upon which treatment decisions are based, and is a strong,
independent predictor of future cardiovascular (CV) events.
However, it is now widely accepted that non-HDL choles-
terol and apolipoprotein (apo) B are somewhat superior
predictors of events.11 Non-HDL cholesterol does not
require an additional measurement as does apo B, and does
not require a fasting sample. Have guideline writers recog-
nized the superiority of non-HDL cholesterol? The NICE
guidelines do recommend that non-HDL cholesterol be used
during follow-up to assess treatment,7 but the ESC/EAS
guidelines still recommend LDL-C and total cholesterol as
the primary target of therapy,6,10 whereas the ACC/AHA
guidelines recommend either LDL-C or non-HDL choles-
terol,8 and the Canadian guidelines recommend LDL-C as
the primary target, with non-HDL cholesterol and apo B as
alternate targets.9
inadequate response to statins, despite the high number needed to
treat to prevent 1 CV event. Proprotein convertase subtilisin/kexin 9
inhibitors lack outcome data to support their use, but are approved for
patients with familial hypercholesterolemia or clinical atherosclerotic
CV disease who require additional LDL-C lowering beyond statins. All
these new guidelines are aimed at improving the problem of under-
treatment of high-risk groups, leading to better outcomes for these
patients.
respectivement le cholest!erol LDL de ! 50 % ou de 30 % à 50 %. Les
statines sont le pilier de traitement de toutes les lignes directrices.
L’!ez!etimibe entraînait une r!eduction du risque relatif de 6,4 % dans la
seule grande !etude sur les r!esultats cliniques au cours de laquelle il
!etait test!e, et est recommand!e chez les patients expos!es à un risque
!elev!e qui ont une r!eponse inad!equate aux statines, en d!epit du nom-
bre !elev!e de sujets à traiter pour empêcher 1 !ev!enement CV. Les
inhibiteurs de la proprot!eine convertase subtilisine/kexine de type 9
manquent de donn!ees sur les r!esultats cliniques pour soutenir leur
utilisation, mais sont approuv!es chez les patients atteints d’une
hypercholest!erol!emie familiale ou d’une maladie CV ath!eroscl!erotique
clinique qui n!ecessitent un hypocholest!erol!emiant pour abaisser le
cholest!erol LDL en plus des statines. Toutes ces nouvelles lignes di-
rectrices visent l’am!elioration du problème de l’insufﬁsance de traite-
ment des groupes expos!es à un risque !elev!e aﬁn d’entraîner de
meilleurs r!esultats cliniques chez ces patients.
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Guideline committees probably all agree on the evidence,
but small variations in the wording of their recommendations
lead to wide variations in practice for seemingly simple issues
like fasting or nonfasting blood samples, and the lipid
parameter to use for risk assessment and treatment decisions.
Some of the other differences among the guidelines are listed
in Table 1.
Risk Assessment
A key principle of all cholesterol guidelines is that the
decision to treat should be on the basis of the level of CV risk,
not the level of cholesterol. It is far more cost-effective to treat
a very high-risk patient with a low-density lipoprotein
cholesterol (LDL-C) level of 2.6 mmol/L (100 mg/dL) than to
treat a very low-risk patient with an LDL-C level of 4 mmol/L
(155 mg/dL).
Certain features are desirable in a risk assessment tool.
Ideally, it should calculate risk for the important clinical CV
end points: CV death, myocardial infarction (MI), and stroke.
In addition, it should be derived from a population similar to
the population in which it will be used. A risk calculator based
on a population in Framingham might not be accurate for a
Bengali resident of Vancouver or an Inuit in Yellowknife.
Ideally, a risk calculator should be convenient or it will not be
used at all.
In Table 2, 4 of the most widely used risk assessment tools
are compared. The Framingham Risk Score (FRS) has been
calibrated in many different populations and has been shown
to be accurate in cohorts from the United States, Australia,
and New Zealand, whereas it overestimates risk in European
cohorts.14 The Canadian guidelines have used the FRS
augmented by a positive family history of CV disease (CVD;
younger than 55 years in ﬁrst-degree male relatives and
younger than 65 years in female relatives) since 2006,
although subsequent evidence from a large European cohort
showed that combining family history with FRS did not
improve classiﬁcation of individuals into clinically relevant
risk categories.15
Although previous American guidelines had recommended
the FRS to assess risk, the ACC/AHA guidelines rejected the
FRS because it was derived from an exclusively white popu-
lation and because the outcome did not include stroke.16
Instead the committee developed the Pooled Cohort Equa-
tions from several large geographically and racially diverse
modern National Heart, Lung, and Blood Institute-sponsored
cohort studies, combined with data from the Framingham
original and Offspring Study cohorts. These equations provide
sex- and race-speciﬁc estimates of 10-year and lifetime risk of
CV death, MI, and stroke for African-American and white
men and women aged 40-79 years.16
In Europe, Systematic Coronary Risk Evaluation
(SCORE) charts are the standard risk assessment tool. They
combine sex, age, total cholesterol, systolic blood pressure,
and smoking status to provide a 10-year risk estimate for CV
death. Versions are available for high- and low-risk European
countries and separate charts have been developed for subjects
with diabetes. A limitation of SCORE is the absence of
nonfatal CV events, speciﬁcally MI and stroke, in the end
point; however, CV deaths include those from hypertensive
heart disease, heart failure, and stroke, as well as coronary
disease.
QRISK2 is the risk assessment tool recommended by the
NICE guidelines. It aggregates patient-level data from all
1243 practices in England and is updated annually. Various
ethnicities in addition to white (Indian, Pakistani, Banglade-
shi, other Asian, black Caribbean, black African, and Chinese)
can be entered, as can medical conditions associated with
increased CV risk such as atrial ﬁbrillation, chronic kidney
disease, and rheumatoid arthritis. The original version was on
the basis of 2.3 million patients aged 35-74 years with
140,000 CV events, and showed superior discrimination and
calibration in British patients compared with the modiﬁed
FRS.17 QRISK2 includes the Townsend index, a marker of
social deprivation, which is derived from the patient’s postal
code. QRISK2 loses some of its accuracy when the postal code
is omitted; but otherwise can be used in non-British patients.
Lifetime Risk
A limitation of most risk assessment tools has been that
their horizon is 10 years. This biases the decision to initiate
treatment toward older individuals, and to a lesser extent,
toward men. The 10-year risk for a 45-year old person is low,
even with multiple risk factors, whereas it is much higher for a
75-year old person with fewer or no risk factors, because risk
increases with age. The ACC/AHA guidelines recommend
consideration of statin therapy for individuals age 40-75 years
with an LDL-C of 1.8-5.0 mmol/L (70-189 mg/dL) if 10-year
risk is ! 7.5%, a level reached by a 65-year-old man and a 71-
year-old woman with optimal risk factors.
However, a 45-year-old woman with an LDL-C of 4.8
mmol/L (185 mg/dL) would not be eligible for treatment
because her 10-year risk is very low. However, her lifetime risk
is high, and accumulating evidence indicates that
Table 1. Differences among major guidelines
Organization Risk assessment
Recommended
treatment
Ezetimibe or PCSK9
inhibitors
ACC/AHA8 Pooled cohort
equation
High- or moderate-
intensity statin to
lower LDL-C by
! 50% or 30%-
50%, respectively
No outcome data
available at the
time of
publication
NICE7 QRISK2 Atorvastatin 20 mg
for primary and
80 mg for
secondary
prevention
No outcome data
available at the
time of
publication
ESC/EAS10 SCORE charts LDL-C targets for
level of risk and
50% LDL-C
reduction for most
high- or very high-
risk patients
Recommended as
second-line Rx
CCS9 Modiﬁed
Framingham
LDL-C < 2 mmol/L
or > 50% LDL-C
reduction
Recommended as
second-line Rx
ACC/AHA, American College of Cardiology/American Heart Association;
CCS, Canadian Cardiovascular Society; ESC/EAS, European Society of
Cardiology/European Atherosclerosis Society; LDL-C, low-density lipopro-
tein cholesterol; NICE, National Institute for Health and Care and Excel-
lence; PCSK9, Proprotein convertase subtilisin/kexin 9; Rx, prescription;
SCORE, Systematic Coronary Risk Evaluation.
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atherosclerosis develops gradually from a young age, and that
correction of hypercholesterolemia at an earlier age would
more effectively reduce lifetime risk, compared with with-
holding treatment until later in life when risk is increased.
Genetic studies indicate that subjects with LDL-C-increasing
mutations, and thus lifelong hypercholesterolemia, are at
greater risk for CV events than are subjects without genetic
mutations but with similar LDL-C levels, although risk is very
high in both groups.18,19
A limitation of earlier initiation of preventive treatment for
people at low short-term, but high long-term risk is the low
compliance levels that have been documented with statins.
Discontinuing a statin in the ﬁrst year or two of treatment is
likely to have little effect in a younger individual with a high
lifetime risk.
LDL-C Treatment Targets
One of the differences among guidelines, and perhaps the
main point of contention, is that some guidelines have speciﬁc
numeric treatment targets whereas others recommend
differing intensities of statin treatment. For example, the new
European guidelines recommend a target LDL-C level of 2.6
mmol/L (100 mg/dL) for high-risk patients, with 1.8 mmol/L
(70 mg/dL) as a target for very high-risk patients.10 They also
recommend a 50% reduction in LDL-C if baseline LDL-C is
between 2.6 and 5.2 mmol/L for high-risk patients or between
1.8 and 3.5 mmol/L for very high-risk patients. In contrast,
the ACC/AHA guidelines recommend high- or moderate-
intensity statin therapy for all patient groups, deﬁned as
treatment expected to reduce LDL-C by ! 50% or 30%-
50%, respectively.8 The Canadian guidelines include a
numeric target as well as a percentage reduction; speciﬁcally,
an LDL-C consistently < 2.0 mmol/L or a > 50% reduction
of LDL-C.9 The NICE guidelines recommend a speciﬁc dose
of a speciﬁc statin, atorvastatin 20 mg for primary and 80 mg
for secondary prevention, with a non-HDL cholesterol
reduction of > 40% as the target for secondary prevention.7
The clinical trial data indicate that for each mmol/L (38.6
mg/dL) reduction in LDL-C, CV events are reduced by 22%
(95% conﬁdence interval [CI], 20%-24%) across a broad
range of baseline LDL-C levels.20 The data do not support the
choice of a speciﬁc target such as 2.6 mmol/L, as opposed to
2.0 or 3.0 mmol/L, or a 50% LDL-C reduction, as opposed
to a 45% or 55% reduction. Beneﬁt is continuous with
increasing amounts of LDL-C reduction, with no speciﬁc
threshold value below which beneﬁt ceases to accrue.
Furthermore, a recent study indicates that although percent-
age of LDL-C reduction adds incremental prognostic value
over statin dose and attained LDL-C level, attained LDL-C
level does not provide additional prognostic value over statin
dose and percentage of LDL-C reduction.21 If the target for a
very high-risk patient is 1.8 mmol/L, a patient with an LDL-C
level of 1.75 mmol/L would not qualify for treatment,
whereas one with an LDL-C of 1.85 mmol/L could achieve
goal with a trivial reduction in LDL-C.22 Despite these con-
siderations, target LDL-C levels are stubbornly entrenched in
some lipid guidelines.
Again, different guideline committees have interpreted the
available evidence differently, and came to different recom-
mendations. ACC/AHA focused on level A evidence from
randomized trials, and thus recommended drugs and doses
tested in these trials. ESC and Canadian guideline writers used
a broader body of evidence, and included observational data
that showed that people reaching lower LDL-C levels have
lower CVD risk and therefore did make recommendations
along these lines.
The stark contrast between the European guidelines with
numerical targets and the ACC/AHA statin intensity-based
guidelines has softened recently. The 2016 ACC expert
consensus decision pathway, while not carrying the weight of
sanctioned guidelines, includes numerical LDL-C targets as a
guide to physicians and patients.23 The new ESC guidelines
concede that “Lowering LDL-C beyond the goals that were
set in the previous EAS/ESC guidelines is associated with
fewer CV events. Therefore, it seems appropriate to reduce
LDL-C as low as possible, at least in patients at very high CV
risk.”10 The ESC guidelines also include the recommendation
for 50% LDL-C reductions for some categories of patients. In
most cases, a 50% LDL-C reduction is the equivalent of a
high-intensity statin.
The response to a speciﬁc dose of a statin is much more
variable than physicians realize, as shown in Figure 1.24 Part of
this variability is due to incomplete adherence to treatment;
however, these data are derived from a clinical trial, where
compliance is expected to be better than in clinical practice. Is
Table 2. A comparison of risk assessment tools
Tool End points included Computer application Advantages Disadvantages
Framingham Risk Score CV death, MI, (stroke, PAD, HF)* CCS appy Well studied cohort Homogeneous white population
ACC/AHA CV death, MI, stroke Yesz Includes African American
individuals; lifetime risk
Accuracy questioned; limited
ethnic representation
SCORE CV death Registration requiredx Calibrated for different European
regions
Limited end point
QRISK2 MI, stroke Yesk Updated yearly; multiple ethnic
groups; countrywide database
Based on United Kingdom data
only
ACC/AHA, American College of Cardiology/American Heart Association; CV, cardiovascular; HF, heart failure; MI, myocardial infarction; PAD, peripheral
arterial disease; SCORE, Systematic Coronary Risk Evaluation.
* The earlier version of the Framingham Risk Score includes CV death and MI only,12 while later versions also include stroke, peripheral artery disease and heart
failure.13
ywww.ccs.ca/en/resources/mobile-apps.
zwww.cvriskcalculator.com/.
xwww.heartscore.org/.
kwww.qrisk.org/.
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the response to treatment related to clinical outcome? Among
patients randomized to placebo or rosuvastatin 20 mg/d,
incidence rates in the Justiﬁcation for the Use of Statins in
Prevention: An Intervention Trial Evaluating Rosuvastatin
(JUPITER) trial for the primary end point were 11.2, 9.2,
6.7, and 4.8 per 1000 person-years for those in the placebo,
no LDL-C reduction, LDL-C reduction < 50%, and LDL-C
reduction ! 50% groups, respectively.25 Thus, it is important
to measure the response to a statin, and to consider more
aggressive therapy, either with drugs or diet or improved
compliance, in poor responders.
Absolute Risk Reduction
The calculation of absolute risk reduction (ARR) for an
individual provides a precise and personalized assessment of
beneﬁt.26-28 The calculation depends upon the following
components; ﬁrst, a 1 mmol/L (38.6 mg/dL) reduction in
LDL-C reduces CV events by 22%, according to the meta-
analysis of the Cholesterol Treatment Trialists’ Collabora-
tion.20 Statin therapy reduces LDL-C by a percentage of
baseline LDL-C. Thus, a 50% reduction in LDL-C produces
a larger numerical reduction in LDL-C when the baseline
LDL-C is high, and thus a larger reduction in CV events. To
calculate ARR, one needs to know baseline LDL-C level,
baseline risk, and amount of LDL-C reduction. Number
needed to treat (NNT) is equal to 100 divided by ARR. It is
generally accepted that an NNT of < 50 is acceptable to
physicians, and an NNT < 30 is acceptable to patients.29
Figure 2 shows the NNT that result from 20% and 50%
LDL-C-lowering for 5-year CVD risks of 5%, 10%, and
20%, at baseline LDL-C levels from 190 mg/dL (5 mmol/L)
to 70 mg/dL (1.8 mmol/L). For a 20% LDL-C reduction, the
NNT is favourable only for very high-risk patients (20%
5-year risk) or for high-risk patients (10% 5-year risk) when
LDL-C is very high. A 50% LDL-C reduction produces a
favourable NNT for all groups except moderate risk (5% 5-
year risk) patients with a baseline LDL-C level of $ 130 mg/
dL (3.4 mmol/L).
A computer application that calculates ARR and NNT on
the basis of individual patient values has not yet been devel-
oped. Such an application would go beyond risk assessment to
provide a measure of the beneﬁt of treatment. NNT should be
balanced against number needed to harm, but for most pa-
tients treated with statins, adverse effects that persist after
treatment discontinuation are very rare. The balance between
beneﬁt and risk with statins is discussed in detail in a recent
review by Collins et al.30
Nonstatin LDL-C-Lowering Options
Fibrates and niacin have not reduced CV events in clinical
trials in which patients were treated with statins, and thus are
n
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Figure 1. Waterfall plot showing the difference in low-density
lipoprotein (LDL) cholesterol between baseline and 1 year for 8000
patients taking rosuvastatin 20 mg/d in the Justiﬁcation for the Use of
Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin
(JUPITER) trial. The patients are lined up with the best responders on
the left and the worst on the right. Modiﬁed from Boekholdt et al.24
with permission from Elsevier.
Figure 2. Number needed to treat (NNT) for 5 years to prevent one
cardiovascular event assuming a 20% reduction in low-density
lipoprotein cholesterol (LDL-C; top) and a 50% reduction in LDL-C
(bottom). The horizontal axis shows baseline LDL-C levels ranging
from 190 to 70 mg/dL (5.0 to 1.8 mmol/L). Red, yellow, and blue
bars depict very high, high, and moderate 5-year cardiovascular risk,
respectively. The black triangles represent achieved LDL-C levels and
the red horizontal line a NNT of 50, often considered to be the
threshold below which treatment is worthwhile. Note that the NNT for
treatment is favourable for many more subgroups with a 50%
compared with a 20% LDL-C reduction. CVD, cardiovascular disease.
Modiﬁed from Robinson27 with permission from Oxford University
Press.
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not recommended by guidelines as add-on therapy.6-9 The
only LDL-C-lowering drug that has been shown to reduce CV
events in statin-treated patients is ezetimibe. In the Improved
Reduction of Outcomes: Vytorin Efﬁcacy International Trial
(IMPROVE-IT),31 18,144 post-acute coronary syndrome
patients were randomized to simvastatin 40 mg/d alone or
with ezetimibe 10 mg/d. The primary end point was a com-
posite of CV death, MI, unstable angina requiring hospitali-
zation, coronary revascularization, and stroke, and patients
were followed for a median of 6 years. The mean LDL-C level
in the group that received ezetimibe was lower, 1.4 compared
with 1.8 mmol/L (53.7 vs 69.5 mg/dL). The primary end
point at 7 years was 32.7% in the combination therapy group
and 34.7% in the simvastatin-alone group, a 6.4% relative
risk reduction (P ¼ 0.016).
The NNT to prevent 1 CV event in IMPROVE-IT was 50
for 7 years of treatment, or 350 for 1 year of treatment. The
application to approve the simvastatin/ezetimibe combination
for the reduction of CV events was rejected by the US Food
and Drug Administration in the United States, after a 10 to 5
vote against approval by an advisory panel, but was approved
by the European Medicines Agency. Subgroup analyses of
IMPROVE-IT showed a signiﬁcant clinical beneﬁt in the
4933 patients with diabetes (hazard ratio [HR], 0.86; 95%
CI, 0.78-0.94; P ¼ 0.001), and in the 2797 patients aged 75
years or older (HR 0.80; 95% CI, 0.70-0.90; P ¼ 0.0003),
but not in nondiabetic patients (HR, 0.98; 95% CI,
0.91-1.04; P ¼ 0.49) or patients younger than 75 years of age
(HR, 0.97; 95% CI, 0.91-1.03; P ¼ 0.34).32
How have these ﬁndings been interpreted by recent
guidelines, and how should they be integrated into clinical
practice? The European and Canadian guidelines recommend
that consideration be given to the combination of ezetimibe
with a statin in selected patients who do not attain treatment
targets with statins alone.9,10 The ACC Task Force on Clin-
ical Expert Consensus Documents recently published an
“expert consensus decision pathway on the role of nonstatin
therapies for LDL-C-lowering.”23 While emphasizing that the
Task Force did not use the rigourous methodology used for
guideline development, they recommended that ezetimibe be
considered for patients with an inadequate response to statin
therapy.
Proprotein convertase subtilisin/kexin 9 (PCSK9) in-
hibitors profoundly reduce LDL-C and in preliminary studies
appear to reduce CV events by approximately 50%.33 Large
clinical trials designed to conﬁrm this beneﬁt are nearing
completion. PCSK9 inhibitors have been shown to reduce
LDL-C levels safely and effectively in statin-intolerant
patients.34 Currently, PCSK9 inhibitors are approved for
patients with familial hypercholesterolemia or clinical
atherosclerotic CVD who require additional LDL-C-lowering
and are recommended for these indications in current
guidelines.9,10,30 However, they are reported to not be cost-
effective for either of these conditions because of their high
cost.35
Success of Guidelines
The implementation of guidelines improves patient
outcomes.36 However, physician adherence and patient
compliance with guidelines is generally thought to be
suboptimal, and undertreatment is common in high-risk
groups, particularly among disadvantaged populations. For
example, in a study across 22 countries in 2016, 66% of
individuals aged 35-70 years with CVD were using statin
therapy in high-income countries such as Sweden or Canada,
but only 27% in upper middle-income countries such as
Poland, Turkey, or Brazil, and approximately 5% in lower-
income countries such as China or India.37 Interventions to
improve physician adherence have a modest effect, at least in
the short-term.38 The incidence of atherosclerotic CVD has
decreased over the past 2 decades in Western Europe,39 the
United States,40 and Canada.41 The contribution of CV
guidelines to this improvement is open to debate. In any case,
it is reasonable to expect that better guidelines adherence by
physicians, as well as better patient compliance, will lead to
better outcomes for patients at risk for CV events.
“The people heard it, and approved the doctrine, and immediately
practiced the contrary.”
dBenjamin Franklin, The Way to Wealth
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